

Index

A

- Adenocarcinomas
 - acinar structures, 10
 - ALK, 136–137
 - BRAF, 132–134
 - CC-10, 87
 - CK7, 85–86
 - 2011 classification, 4
 - DC-LAMP, 87
 - diagnosis, 9
 - EGFR, 129–131
 - favor, 8
 - HER2, 134–135
 - histologic features, 4, 5
 - 2011 IASLC/ATS/ERS classification, 9
 - immunoreactivity, 8
 - KRAS, 131–132
 - mimickers of
 - bronchial cell hyperplasia, 160
 - bronchial cells reaction, 158–160
 - exfoliative cytology, 155–156
 - goblet cell hyperplasia, 160–162
 - peribronchiolar metaplasia, 160, 161
 - pneumocytes hyperplasia, 156, 158
 - small tissue biopsy, 156–157
 - type II pneumocytes reaction, 155
 - miscellaneous conditions
 - cytomorphologic changes, 165
 - granulomas, 168, 169
 - hepatocytes, 168
 - mesothelial cells, 167–168
 - metaplastic squamous cells, 166
 - pulmonary infarct, 166
 - therapy-related changes, 165
 - viral infections, 166–167
 - Napsin A, 84–85
 - nomenclature, 4, 6
 - PI3K pathway activation, 135–136
 - RET, 138–139
 - ROS1, 137–138
 - surfactant protein-A/B, 86–87
 - TTF-1, 83
- American College of Chest Physicians (ACCP), 17
- American Thoracic Society (ATS), 2
- Anaplastic lymphoma kinase (ALK)
 - immunohistochemistry
 - 5A4 clone, 118
 - ALK-1 clone, 118
 - D5F3 clone, 118
 - diagnosis, 117–118
 - scoring system, 118–120
 - in lung cancer, 104–106, 136–137
- Ancillary immunohistochemical techniques
 - adenocarcinoma (*see* Adenocarcinoma)
 - adenomarkers, 77, 78
 - large cell carcinoma, 87
 - salivary gland-type carcinoma, 89
 - sarcomatoid carcinoma, 88–89
 - small specimens, 89–90
 - squamous cell carcinoma (*see* Squamous cell carcinoma)
 - squamous markers, 77, 78
- Anti-CK5/6, 79–80
- Aspartyl protease 4, 84–85
- Association for Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS), 40

B

Basaloid carcinoma, 87
 34βE12, 79
 Bevacizumab, 3
 BRAF, 132–134

C

Carcinomas
 core biopsies and cell blocks, 68–69
 immunohistochemistry for, 70
 molecular testing, 70–71
 triage, 68, 69
 Cetuximab, 102
 Chemotherapy, 3
 Clara cell protein 10 (CC-10), 87
 Clear cell tumor, 172–173
 Convex probe endobronchial ultrasound (CP-EBUS)
 disadvantages, 20, 21
 institutional protocol, 23
 needles, 21
 puncture site, 22
 sampling, 21
 scope size, 20–21
 suction syringe, 22
 target identification, 22
 ultrasonographic survey, 23
 uses, 20
 Core biopsy, 41–42
 Crizotinib, 117, 121

D

DC-LAMP (CD208), 87
 Desmocollin 3 (DSC3), 80
 Desmoglein 3 (DSG3), 80
 Diff-Quik stain, 66, 73, 74
 Diffuse alveolar damage (DAD), 163–164
 Discoidin domain receptor (DDR), 144

E

Electromagnetic navigational bronchoscopy (ENB)
 characteristics, 33–34
 iLogic System, 32
 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
 characteristics, 24
 complications, 24
 limitations, 24–25
 meta-analysis, 23

multidisciplinary
 negative predictive value, 25
 nondiagnostic findings, 25
 role, 26
 surgical sampling, 26
 treatment algorithm, 26–27

ROSE, 25

staging and diagnosis, 23
 surgical mediastinoscopy, 23
 transbronchial approach, 25

Epidermal growth factor receptor (EGFR)

immunohistochemistry
 application, 113–115, 121–123
 detection of, 110
 monoclonal antibodies, 111
 scoring system, 111–113
 specificity of, 116
 TKI therapy in, 115–116
 in lung cancer, 102–104, 129–131
 squamous cell carcinomas, 140, 145

ERBB2 (HER2), 134–135

Erlotinib, 102

Ethylenediaminetetraacetic acid (EDTA), 99

European Respiratory Society (ERS), 2

F

Fibroblast growth factor receptor (FGFR),
 142–143

Fine needle aspiration (FNA), 42–45, 62–65

Fluorescence in situ hybridization, 100

G

Gefitinib, 102

Goblet cell hyperplasia, 160–162

Granular cell tumor, 173–174

Granulomas, 168

H

Hepatocytes, 168

I

Immunohistochemistry

 ALK rearrangement
 5A4 clone, 118
 ALK-1 clone, 118
 D5F3 clone, 118
 diagnosis, 117–118
 scoring system, 118–120

 BRAF, 110

 for carcinomas, 70

- EGFR mutation
 - application, 113–115, 121–123
 - detection of, 110
 - monoclonal antibodies, 111
 - scoring system, 111–113
 - specificity of, 116
 - TKI therapy in, 115–116
- ROS1, 121
- small biopsy specimens
 - EGFR mutation in, 110
 - mutation-specific antibodies in, 113–115
- Insulin-like growth factor-1 receptor (IGF1R), 144
- International Association for Study of Lung Cancer (IASLC), 2
- Invasive papillomatosis, 176–177

- K**
- Kirsten rat sarcoma viral oncogene homolog (KRAS), 106, 131–132

- L**
- Large cell carcinoma, 87
- Liquid-based preparations (LBP)
 - advantages, 50
 - disadvantages, 51
- Lung cancer
 - adenocarcinomas (*see* Adenocarcinomas)
 - adenosquamous carcinomas, 139
 - bevacizumab, 3
 - chemotherapy, 3
 - CP-EBUS
 - disadvantages, 20, 21
 - institutional protocol, 23
 - needles, 21
 - puncture site, 22
 - sampling, 21
 - scope size, 20–21
 - suction syringe, 22
 - target identification, 22
 - ultrasonographic survey, 22
 - uses, 20
 - diagnosis, 1, 2
 - EBUS-TBNA
 - characteristics, 24
 - complications, 24
 - limitations, 24–25
 - meta-analysis, 23
 - multidisciplinary, 25–27
 - multimodality approach, 25–27
 - ROSE, 25
 - staging and diagnosis, 23
 - surgical mediastinoscopy, 23
 - transbronchial approach, 25
 - ENB, 33–34
 - histologic types, 2
 - molecular targeted therapy classification, 3–4
 - navigational bronchoscopy, 32–33
 - needle core biopsy, 40
 - nonsurgical sampling techniques, 16
 - pathologic sampling, 17–18
 - ACCP, 17
 - American College of Radiology, 17
 - characteristics, 17
 - peripheral lesions, pathologic sampling of, 27–28
 - primary and metastatic lesions, 15
 - radiographically guided needle sampling, 28–30
 - radiology or laboratory testing, 15
 - RP-EBUS, 19–20, 31–32
 - sampling central lesions, 18–19
 - small biopsy material and cytology
 - adenocarcinoma (*see* Adenocarcinoma)
 - poorly differentiated carcinoma, 5, 6
 - squamous cell carcinomas (*see* Squamous cell carcinoma (SCC))
 - therapy for, 1
 - TTNA
 - ACCP guidelines, 30
 - characteristics, 30
 - complications, 31
 - vs. ENB, 34
- Lymphocytes, 169
- Lymphoepithelioma-like carcinoma, 87
- Lymphoproliferative disorders, 71–72

- M**
- Mesothelial cells, 167–168
- MET*, 145
- Mimic lung carcinoma
 - adenocarcinoma (*see* Adenocarcinoma, mimickers of)
 - clear cell tumor, 172–173
 - granular cell tumor, 173–174
 - meningothelial-like nodules, 170–171
 - neuroendocrine carcinoma (*see* Neuroendocrine carcinoma)
 - papillomas, 176–177
 - pneumocytoma, 174–176
 - primary pleuropulmonary thymoma, 177–179
 - pulmonary hamartoma, 171–172
 - squamous cell carcinoma (*see* Squamous cell carcinoma (SCC), mimickers of)

Molecular diagnosis

- ALK rearrangements, 104–106
- clinical application, 97
- c-MET* amplifications, 106
- cryopreservation, 98
- EDTA, 99
- EGFR, 102–104
- fluorescence in situ hybridization, 100
- KRAS, 106
- polymerase chain reaction, 100–102
- pre-analytical variables, 97–99
- ROS1 rearrangement, 106
- sample types, 97–99

N

- Napsin A, 84–85
- Necrotizing sialometaplasia, 164
- Neuroendocrine carcinoma
 - lymphocytes, 169
 - naked nuclei, 169–170
 - reserve cell hyperplasia, 168–170

P

- p40*, 82–83
- p63*, 80–82
- Papanicolaou stain, 66, 73, 74
- Peribronchiolar metaplasia (Lambertosis), 160
- PI3K pathway, 135–136, 143
- Platelet-derived growth factor receptor (PDGFR), 144–145
- Pleuropulmonary thymomas, 177–179
- Pneumothorax, 31
- Polymerase chain reaction (PCR), 100–102
- Pulmonary hamartoma, 171–172

R

- Radial probe endobronchial ultrasound (RP-EBUS), 19–20, 31–32
- Rapid on-site evaluation (ROSE), 25
 - absence of, 44
 - advantages, 42
 - cell blocks, 51–53
 - disadvantages, 44–45
 - efficiency of, 65
 - fine needle aspirations with, 62–65
 - formalin, 50
 - FTA cards, 51
 - LBP, 50–51
 - lung nodule aspirates, 43
 - lymph node assessment, 45–47
 - specimen preparation, 43

- telepathology/telectyology, 48–49
- tissue preservation, 49
- touch preparations, 47–48
- without FNA, 65–66

- Reserve cell hyperplasia, 168–170
- RET*, 138–139

S

- Salivary gland-type carcinoma, 89
- Sarcomatoid carcinoma, 88–89
- Sclerosing hemangioma, 174–176
- Small cell lung cancer (SCLC), 2, 145–146
- Small specimens
 - carcinomas
 - core biopsies and cell blocks, 68–69
 - immunohistochemistry for, 70
 - molecular testing, 70–71
 - triage, 68, 69
 - cytological preparations, 73
 - Diff-Quik stain, 73
 - liquid-based preparations, 74
 - in non-small cell carcinoma, 89–90
 - optimization
 - carcinomas, 68–71
 - fine needle aspirations, 66–67
 - with navigational bronchoscopy, 72
 - touch preparations, 67–68
- Papanicolaou stain, 73
- practice gap with, 40
- ROSE
 - efficiency of, 65
 - fine needle aspirations with, 62–65
 - without FNA, 65–66
- triage
 - carcinomas, 68
 - infectious processes and granulomas, 72
 - lymphoproliferative disorders, 71–72
- Solitary peripheral nodule (SPN)
 - bronchoscopic sampling, 32
 - CT-guided sampling, 28–29
 - nature, 28
- Solitary squamous papillomas, 176–177
- Squamous cell carcinoma (SCC)
 - anti-CK5/6, 79–80
 - CK14, 80
 - classification, 4, 5
 - DDR2* mutations, 144
 - DSG3*, 80
 - EGFR, 140
 - EGFR vIII, 145
 - emerging oncogenic targets, 140–142
 - favor, 8
 - FGFR, 142–143

genotype-driven therapy, 146–147
IGF1R, 144
immunoreactivity, 8
MET, 145
mimickers of
 atypical squamous metaplasia, 162
 cavitary infections, 162–163
 diffuse alveolar damage, 163–164
 eactive squamous changes, 162
 necrotizing sialometaplasia, 164
 tracheostomy, 162
nomenclature, 4, 6
p40, 82–83
p63, 80–82
PDGFR, 144–145
PI3K pathway, 143
SCLC, 145–146
34βE12, 79
VEGFR, 139–140

Sugar tumor, 172–173
SurePath™, 50, 66, 74
Surfactant protein-A (Sp-A), 86
Surfactant protein-B (Sp-B), 86–87

T

Telepathology/telectology, 48–49
ThinPrep®, 50, 66, 74
Thyroid transcription factor-1 (TTF-1), 83
Transthoracic needle aspiration (TTNA)
 ACCP guidelines, 30
 characteristics, 30
 complications, 31
 vs. ENB, 34
Transthoracic needle biopsy (TTNB),
 30, 34
Tyrosine kinase inhibitors (TKI),
 3, 115–116